"That status quo frequently involves pharmaceutical companies’ making minor changes to existing drugs to gain additional market exclusivity, which keeps prices high." - @ChuckGrassley and @SenBillCassidyhttps://www.nationalreview.com/2019/10/prescription-drug-pricing-reduction-act-bipartisan-plan-make-prescription-drugs-affordable/ …
"In the case of improvements to medicines that are innovations, this is justified. However, it appears that exclusivities are being granted where it is not justified," - @ChuckGrassley and @SenBillCassidy wrote in @NRO.
-
-
"The trick is to rein in gimmicks and abuses while maintaining incentives for true innovation that advances science. There must be a system that facilitates breakthrough treatments, but it needs to be sustainable for patients and taxpayers." -
@ChuckGrassley and@SenBillCassidyShow this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.